meningococcal group B vaccine

(redirected from Trumenba)

meningococcal group B vaccine

(me-nin-go-kok-al groop B vax-seen),

Bexsero

(trade name),

Trumenba

(trade name)

Classification

Therapeutic: vaccines immunizing agents
Pharmacologic: antigens
Pregnancy Category: B

Indications

Bexsero—Provides active immunization against invasive meningococcal disease caused by 3 strains of Neisseria meningitidis serogroup B (strains prevalent in the US). Tremenba—Provides active immunization against invasive meningococcal disease caused by 4 strains of Neisseria meningitidis serogroup B (strains prevalent in the US).

Action

Induces production of antibodies to several strains of serogroup B Neisseria meningitidis.

Therapeutic effects

Prevention of invasive meningococcal disease.

Pharmacokinetics

Absorption: Well absorbed following IM administration.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile (antibody response)

ROUTEONSETPEAKDURATION
IMwithin 2 mounknownunknown

Contraindications/Precautions

Contraindicated in: Severe allergic reaction to a previous dose; Latex allergy (Bexsero tip caps contain latex).
Use Cautiously in: Geriatric: Safe and effective use in patients >65 yr has not been established; Lactation: Use cautiously if breastfeeding; Obstetric: Use during pregnancy only if clearly needed; Pediatric: Safe and effective use in children <10 yr not established (>90% risk of fever in infants <12 mo).

Adverse Reactions/Side Effects

Central nervous system

  • fatigue (most frequent)
  • headache (most frequent)

Gastrointestinal

  • nausea (most frequent)
  • diarrhea
  • vomiting

Local

  • injection site reactions (most frequent)

Musculoskeletal

  • arthralgia (most frequent)
  • mylagia (most frequent)

Miscellaneous

  • allergic reactions including anaphylaxis
  • chills (most frequent)
  • fever
  • syncope

Interactions

Drug-Drug interaction

Concurrent use of immunosuppressives may ↓ the desired immune response.

Route/Dosage

Bexsero

Intramuscular (Adults and Children 10–25 yr) Two 0.5 ml doses one mo apart.

Trumenba

Intramuscular (Adults and Children 10–25 yr) 0.5 ml followed by a second dose 2 mo later and a third dose 4 mo after the second dose.

Availability

Suspension for IM injection (Bexsero tip caps contain latex): 0.5 ml in pre-filled syringes

Nursing implications

Nursing assessment

  • Monitor for signs and symptoms of allergic reaction (dyspnea, rash, hives, swelling of face, lips, or throat). Keep epinephrine, an antihistamine, and resuscitation equipment close by in the event of an anaphylactic reaction.
  • Assess for latex allergy. Bexsero tip cap contains latex.
  • Assess for syncope. Make patient is sitting or lying down during and immediately following injections.

Potential Nursing Diagnoses

Risk for infection (Indications)

Implementation

  • Intramuscular: Shake syringe vigorously for a homogenous white suspension; do not use if solution has separated, discolored, or contains particulate matter. Administer 0.5 mL IM into deltoid muscle of upper arm. Do not mix with other vaccines in same syringe.

Patient/Family Teaching

  • Explain purpose of vaccine to patient/parent. Emphasize need for 2 doses of immunization series for Bexseroor 3 doses for Tremenba.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Prevention of invasive meningococcal disease including meningitis.
References in periodicals archive ?
The uptake of meningococcus B vaccines remains relatively slow, with GlaxoSmithKline's Bexsero being administered to more patients than Pfizer's Trumenba, especially by surveyed ID specialists.
The two vaccines licensed by the Food and Drug Administration are Trumenba (by Pfizer), a three-dose series, and Bexsero (GlaxoSmithKline), a two-dose series; they are indicated for preventing meningococcal disease caused by Neisseria meningitidis serogroup B in people aged 10-25 years.
Food and Drug Administration licensed the two vaccines - trade names Bexsero and Trumenba - based on data that suggested that they prevent the specific Type B bacteria from infecting the bloodstream or the brain and spinal cord's protective membranes, causing meningitis or meningoccocemia, two rare but potentially fatal diseases, said Lucy McNamara, a CDC scientist working on the study.
meningitidis serogroup B in people aged 10-25 years in the United States: Trumenba (Pfizer), licensed in October 2014, and Bexsero (Novartis Vaccines and Diagnostics), in January 2015.
For these 11 medicines, see revenues to 2025: -- Zoster and Malaria vaccines (GSK) -- 9-valent HPV agents (Merck) -- Hexavalent paediatric vaccines (Sanofi) -- Dengue fever products (Sanofi) -- Trumenba vaccines (Pfizer).
Food and Drug Administration announced today the approval of Trumenba, the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
The report also highlights and analyzes various brands of Men B vaccines recently approved, such as Bexsero and Trumenba, as well as the vaccine currently in pipeline - NmVac-4DT.
Students will be able to get their first or second dose of the three-dose vaccine, known under the brand name Trumenba, at the mass clinic that runs Monday through Wednesday.
FDA recently approved two Men B vaccines: Trumenba by Pfizer in October 2014 and Bexsero by Novartis in January 2015.
Adding to the challenge is that students must get two follow-up doses, given at two and six months respectively after the initial dose, to get the greatest protection from the vaccine, which goes by the brand name Trumenba and is developed by Pfizer.
The vaccine, called Trumenba, developed by Pfizer and approved by the U.
For these 11 medicines, see revenues to 2025: - Zoster and Malaria vaccines (GSK) - 9-valent HPV agents (Merck) - Hexavalent paediatric vaccines (Sanofi) - Dengue fever products (Sanofi) - Trumenba vaccines (Pfizer).